[{"id":"32bf2d91-1dd7-46f9-979d-dab7e5ee0240","acronym":"","url":"https://clinicaltrials.gov/study/NCT05851014","created_at":"2023-05-09T14:04:35.821Z","updated_at":"2024-07-02T16:35:48.551Z","phase":"Phase 3","brief_title":"A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer","source_id_and_acronym":"NCT05851014","lead_sponsor":"Genor Biopharma Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • lerociclib (G1T38)"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 01/14/2022","start_date":" 01/14/2022","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2027","study_completion_date":" 01/30/2027","last_update_posted":"2023-05-09"},{"id":"78af937c-f332-4ea8-aa7b-a65473acf478","acronym":"","url":"https://clinicaltrials.gov/study/NCT02983071","created_at":"2021-01-17T17:46:47.681Z","updated_at":"2024-07-02T16:35:55.491Z","phase":"Phase 1/2","brief_title":"G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT02983071","lead_sponsor":"G1 Therapeutics, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • lerociclib (G1T38)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 01/01/2017","start_date":" 01/01/2017","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2023-02-15"},{"id":"b934347a-0510-4324-94a6-6918932c4aae","acronym":"LEONARDA-1","url":"https://clinicaltrials.gov/study/NCT05054751","created_at":"2021-09-23T17:53:06.942Z","updated_at":"2024-07-02T16:36:09.004Z","phase":"Phase 3","brief_title":"GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT05054751 - LEONARDA-1","lead_sponsor":"Genor Biopharma Co., Ltd.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • lerociclib (G1T38)"],"overall_status":"Recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 09/10/2021","start_date":" 09/10/2021","primary_txt":" Primary completion: 10/31/2023","primary_completion_date":" 10/31/2023","study_txt":" Completion: 01/31/2024","study_completion_date":" 01/31/2024","last_update_posted":"2022-06-13"},{"id":"ac77f744-c998-4057-9eff-101c932cfc2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05337657","created_at":"2022-04-20T15:53:50.168Z","updated_at":"2024-07-02T16:36:11.809Z","phase":"Phase 1","brief_title":"A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT05337657","lead_sponsor":"Genor Biopharma Co., Ltd.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • lerociclib (G1T38)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 06/02/2021","start_date":" 06/02/2021","primary_txt":" Primary completion: 12/12/2023","primary_completion_date":" 12/12/2023","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2022-04-20"}]